Abstract: Pharmacokinetics and Safety Following Co-Administration of Nalbuphine Extended-Release with Pirfenidone or Nintedanib: A Phase 1 Drug-Drug Interaction Study

Presenter: James Cassella, PhD

Session: A75 Late Breaking Abstracts in Clinical Problems

Abstract: The Effect of Nalbuphine Extended Release on Cough Bouts in Patients with Idiopathic Pulmonary Fibrosis from a Phase 2b Randomized Clinical Trial (CORAL)

Presenter: Jaclyn Smith, PhD, MBChB

Session: A110 Closing the Gap: Advances in Pulmonary Fibrosis

Abstract: Nalbuphine Extended Release Reduces Cough Bouts in Patients with Refractory Chronic Cough in the Phase 2a RIVER Trial

Presenter: Jaclyn Smith, PhD, MBChB

Session: B29 The Latest in Airway Symptoms and Disease

Abstract: Evaluating the Burden of Chronic Cough in Patients with Interstitial Lung Disease: A US Survey-based Analysis of Its Effects on Daily Life and Emotional and Social Well-being

Presenter: Jeffrey J. Swigris, DO, MS

Session: B39 Breath and Burden: Diffuse Lung Diseases and Daily Life

Abstract: A Phase 2b Trial (CORAL) of Nalbuphine Extended-Release Tablets in Patients with Idiopathic Pulmonary Fibrosis Experiencing Chronic Cough: Primary and Subgroup Analyses

Presenter: Philip L. Molyneaux, MD, PhD

Session: B95 Fibrosis, Cough, and Inflammation: Treatment Strategies in ILD

Abstract: The Effect of Nalbuphine Extended-Release Tablets on Breathlessness in Patients with Idiopathic Pulmonary Fibrosis Experiencing Chronic Cough from the Phase 2b CORAL Trial

Presenter: Donald A. Mahler, MD

Session: C103 The Next Frontier of Therapy in Pulmonary Fibrosis